Crossmark

Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease

Crossref DOI link: https://doi.org/10.1038/s41443-019-0127-x

Published Online: 2019-02-11

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Masterson, Thomas

Patel, Premal

Ramasamy, Ranjith https://orcid.org/0000-0003-1387-7904
License Information

Text and Data Mining valid from 2019-02-11
More Information

Article History

Received: 9 December 2018

Accepted: 17 December 2018

First Online: 11 February 2019

Compliance with ethical standards

:

: TM and RR are the recipients of an investigator-initiated research grant from Endo Pharmaceuticals